Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 66

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 66
---
 that the forecasted results will necessarily reflect actual future results.

The unaudited prospective financial information set forth in the forecasts included under the section titled “The
Transactions—Certain Financial Projections Utilized by the Special Committee and the Enfusion Board” was not prepared with a view toward compliance with published guidelines of the SEC or the guidelines established by the American
Institute of Certified Public Accountants for preparation or presentation of prospective financial information. Further, any forward-looking statement speaks only as of the date on which it is made, and neither Clearwater nor Enfusion undertakes any
obligation, other than as required by applicable law, to update, correct or otherwise revise the unaudited prospective financial information included in this Proxy Statement/Prospectus to reflect events or circumstances after the date such
prospective financial information was prepared or to reflect the occurrence of anticipated or unanticipated events or circumstances, even in the event that any or all of the assumptions underlying any such prospective financial information are no
longer appropriate (even in the short term).

The unaudited prospective financial information of Enfusion included in this Proxy
Statement/Prospectus has been prepared by, and is the responsibility of, the management of Enfusion. Neither Ernst & Young LLP nor any other independent accountant has compiled, reviewed, examined, performed any other assurance procedures,
or expressed any form of assurance with respect to the prospective financial information included in this Proxy Statement/Prospectus. The report of Ernst & Young LLP incorporated by reference in this Proxy Statement/Prospectus relates to
Enfusion, Inc.’s historical audited financial statements and does not extend to the unaudited prospective financial information and should not be read to do so. Neither Clearwater’s independent auditors, nor any other independent
accountants, have compiled, examined, or performed any procedures with respect to the prospective financial information contained herein, nor have they expressed any opinion or any other form of

38

assurance on such information or its achievability, and assume no responsibility for, and disclaim any association with, the prospective financial information. See the section titled “The
Transactions—Certain Financial Projections Utilized by the Special Committee and the Enfusion Board” for more information.

The opinion of the Special Committee’s financial advisor will not reflect changes in circumstances between the date of such opinion and the completion of the Transactions.

At a meeting of the Special Committee held on January 10, 2025, Goldman Sachs rendered its oral opinion to the Special Committee,